Evidence map›Paper›PMID 39994498›Full record

ArticleDrug and alcohol review2025

A comparison of the United Kingdom, Australian and Japanese hangover product market.

Maureen N Zijlstra, Sanne E Schulz, Emina Išerić, Quinten Barré, Andrew Scholey, Joris C Verster

Abstract readComparative Study
In one paragraph

Article in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Effects of ParaprobioticJournal of microbiology and biotechnology · 2025
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maureen N ZijlstraUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, Netherlands.ORCID 0009-0003-8909-4073
Sanne E SchulzUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, Netherlands.ORCID 0009-0000-6988-9889
Emina IšerićUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, Netherlands.ORCID 0009-0000-5263-2833
Quinten BarréUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, Netherlands.ORCID 0009-0009-7292-7079
Andrew ScholeyNutrition Dietetics and Food, School of Clinical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0003-4484-5462
Joris C VersterUtrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, Netherlands.ORCID 0000-0002-6455-2096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of products to prevent or reduce alcohol hangovers is increasingly popular. The aim of this study was to evaluate and compare the alcohol hangover product markets of the United Kingdom, Australia and Japan.

methodsThe website www.Amazon.com was searched, using the terms 'hangover treatment' and 'hangover cure', to identify hangover products sold in the United Kingdom, Australia and Japan. Dosage forms, ingredients and their amounts per serving were recorded and compared between the three countries.

resultsThe market evaluations for the United Kingdom and Australia each revealed N = 19 hangover products, and 24 hangover products were found for Japan. The products from the three markets were quite distinct, with none of the hangover products being marketed in all three countries. The most popular ingredients in United Kingdom were potassium (63.2%), sodium (57.9%) and vitamin C (52.6%). The most common ingredients in Australia were vitamin B1, vitamin B6, vitamin B12 and sodium (all 47.4%). In Japan, curcumin (45.8%), L-ornithine (29.2%), vitamin C (20.8%) and vitamin B2 (20.8%) were the most popular ingredients. Most popular dosage forms also differed between the countries, with powders being most popular in the United Kingdom (42.1%), tablets in Japan (50.0%), and capsules (31.6%) and drinks (26.3%) in Australia. DISCUSSION AND

conclusionsBoth ingredients and dosage forms of hangover products differed between the United Kingdom, Australia and Japan. Products also differed from the United States, illustrating the importance of cross-cultural comparisons. As these are currently lacking, double-blind, placebo-controlled clinical trials are needed to demonstrate the efficacy and safety of marketed hangover products.

Indexed as

Alcohol DrinkingAlcoholic BeveragesAlcoholic IntoxicationAustraliaDosage FormsHumansJapanUnited KingdomDosage FormsAustraliahangoverJapantreatmentUK

Identifiers

PMID39994498
PMCPMC12117289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.